drugset / Trial / NCT01175200
Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.
Completed
82 enrolled
Ascopharm Groupe Novasco
Groupe Hospitalier Pitie-Salpetriere · collabMedco Health Solutions, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will establish the optimal therapeutic strategy for patients with a coronary artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for treatment/prevention of GI ulceration.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Comparator | Lansoprazole | Other / unclassified | — | — |
| Comparator | Prasugrel | Small molecule | — | — |